Meeting
2017 ASCO Annual Meeting
A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).
Authors
Ryan Phillips
Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Ryan Phillips , Noura Radwan , Ashley Ross , Steven P. Rowe , Michael A. Gorin , Emmanuel S. Antonarakis , Curtiland Deville , Stephen C Greco , Samuel R. Denmeade , Channing Judith Paller , Daniel Y. Song , Maximilian Diehn , Hao Wang , Michael Anthony Carducci , Kenneth J. Pienta , Martin G. Pomper , Theodore L. DeWeese , Adam P. Dicker , Mario A. Eisenberger , Phuoc T. Tran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02680587
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5094)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5094
Abstract #
TPS5094
Poster Bd #
164a
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
First Author: Phuoc T. Tran
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz
Poster
2020 Genitourinary Cancers Symposium
A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer.
First Author: Isobel Porter
Poster
2024 ASCO Genitourinary Cancers Symposium
Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.
First Author: Jonathan David Tward